Cargando…

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study

BACKGROUND: The purpose of this study was to explore a new estrogen receptor (ER) and/or progesterone receptor (PR)+ and human epidermal growth factor receptor 2 (HER2)− breast cancer prognostic model, called the extended Cox prognostic model, for determining the cutoff values for multiple continuou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yiqun, Li, Xizhou, Wu, Ying, Cui, Wenting, Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555115/ https://www.ncbi.nlm.nih.gov/pubmed/36224558 http://dx.doi.org/10.1186/s12957-022-02790-0

Ejemplares similares

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer
por: Liu, Qian, et al.
Publicado: (2023)

The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China
por: Song, Qingkun, et al.
Publicado: (2013)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana
por: Seshie, Bernard, et al.
Publicado: (2015)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+)
por: Wang, Xinli, et al.
Publicado: (2023)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients
por: Chen, Zhi, et al.
Publicado: (2022)

Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status
por: Ha, Seon-Ah, et al.
Publicado: (2009)

The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China
por: Xie, Fei, et al.
Publicado: (2022)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images
por: Rawat, Rishi R., et al.
Publicado: (2020)

ODP433 An increased in AIPB expression in Triple Negative (ER-/PR-/Her2-) Breast Tumors reduces estradiol synthesis
por: Downs, William V, et al.
Publicado: (2022)

THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol
por: Patrawala, Mahjabin, et al.
Publicado: (2023)

Identification of long non-coding RNA-mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER(+)/PR(+), HER2(−) and triple negative breast cancer
por: Du, Zhengwei, et al.
Publicado: (2019)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
por: Dai, Xiaofeng, et al.
Publicado: (2014)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER(−)/PR(−)/Her2(−) Human Breast Cancer Cells
por: Novikov, Olga, et al.
Publicado: (2016)

Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status
por: Wu, Huizhe, et al.
Publicado: (2017)

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
por: Howat, William J, et al.
Publicado: (2014)

Genetic and clinical landscape of ER + /PR- breast cancer in China
por: Dai, Danian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ab8139s54g0hvaquvkmlqpk37b